375.16

1.51% 6.2443

Bio Rad Laboratories Inc (BIO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Bio Rad Laboratories Inc stock is traded at $375.16, with a volume of 72,343. It is up +1.51% in the last 24 hours and up +8.96% over the past month. Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Previous Close:

$368.92

Open:

$363.14

24h Volume:

72,343

Relative Volume:

0.27

Market Cap:

$10.39B

Revenue:

$2.56B

Net Income/Loss:

$-1.33B

P/E Ratio:

-64.13

EPS:

-5.85

Net Cash Flow:

$177.42M

1W Performance:

+12.92%

1M Performance:

+8.96%

6M Performance:

+33.83%

1Y Performance:

+30.09%

1-Day Range:

$361.13

$376.04

1-Week Range:

$328.17

$376.04

52-Week Range:

$262.12

$376.04

Bio Rad Laboratories Inc Stock (BIO) Company Profile

Name

Bio Rad Laboratories Inc

Sector

Healthcare (1181)

Industry

Medical Devices (155)

Phone

(510) 724-7000

Address

1000 ALFRED NOBEL DRIVE, HERCULES

Employee

8,030

Twitter

@BioRadLifeSci

Next Earnings Date

2024-10-30

Latest SEC Filings

BIO's Discussions on Twitter

Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-01-24	Upgrade	Citigroup	Neutral → Buy
Aug-28-24	Initiated	Wells Fargo	Equal Weight
Jun-03-24	Resumed	Jefferies	Hold
Apr-03-24	Downgrade	Citigroup	Buy → Neutral
Dec-07-23	Initiated	UBS	Buy
Jun-16-23	Initiated	Wells Fargo	Overweight
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Aug-25-22	Initiated	Credit Suisse	Outperform
Jan-28-22	Reiterated	Citigroup	Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-17-18	Initiated	Goldman	Buy
Sep-20-18	Initiated	Morgan Stanley	Equal-Weight
Feb-16-18	Downgrade	CL King	Buy → Neutral
Jul-13-17	Initiated	Wells Fargo	Outperform
Jun-28-17	Upgrade	Deutsche Bank	Hold → Buy
Jan-18-17	Initiated	Deutsche Bank	Hold
Oct-13-16	Initiated	CL King	Buy
May-06-15	Reiterated	Jefferies	Buy
Dec-18-09	Initiated	Maxim Group	Buy
Nov-06-09	Initiated	Jefferies & Co	Buy
Jul-17-09	Initiated	Soleil	Buy
Sep-26-07	Initiated	Banc of America Sec	Buy
Feb-23-07	Downgrade	Robert W. Baird	Outperform → Neutral

View All

Bio Rad Laboratories Inc Stock (BIO) Latest News

10:32 AM

Bio-Rad's SWOT analysis: stock outlook amid operational gains, sector headwinds - Investing.com

10:32 AM

05:22 AM

Harbor Capital Advisors Inc. Purchases 3,840 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat

05:22 AM

01:54 AM

Vanguard Group Inc's Strategic Reduction in Bio-Rad Laboratories Inc Shares - GuruFocus.com

01:54 AM

Nov 04, 2024

StarBright Yellow 561: A reliable alternative to PE-tandem dyes - News-Medical.Net

Nov 04, 2024

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO) - Simply Wall St

Nov 04, 2024

Epigenetics Market Types and Applications, Drivers, Ongoing - openPR

Nov 04, 2024

Nov 03, 2024

Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Position Raised by Van ECK Associates Corp - MarketBeat

Nov 03, 2024

Nov 02, 2024

StockNews.com Upgrades Bio-Rad Laboratories (NYSE:BIO) to "Buy" - MarketBeat

Nov 02, 2024

Bio-Rad stock hits 52-week high at $365.65 amid robust growth - Investing.com Australia

Nov 02, 2024

Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

Nov 02, 2024

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 02, 2024

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket - MSN

Nov 02, 2024

Nov 01, 2024

Bio-Rad stock hits 52-week high at $365.65 amid robust growth By Investing.com - Investing.com South Africa

Nov 01, 2024